Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 397 (CSE: HITI) (NYSE: ACB) (TSX: ACB) (TSXV: RLV) (OTC: PSYC) (CSE: SHRM)


Delta, Kelowna, BC - April 13, 2020 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 397 (CSE: HITI) (NYSE: ACB) (TSX: ACB) (TSXV: RLV) (OTC: PSYC) (CSE: SHRM)


Hear Investor ideas cannabis potcast on iTunes

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few public announcements.

High Tide Inc. (CSE:HITI) (OTCQB:HITIF), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, announced that the Canna Cabana retail cannabis stores in Hamilton, Sudbury and Toronto have re-opened in compliance with the Province's permissible scope of operations. The Hamilton location re-opened on April 9,

2020 and the Sudbury and Toronto locations re-opened on April 11, 2020.

High Tide continues to operate 30 branded retail cannabis stores across Canada, in addition to Aurora Cannabis' (NYSE:ACB) (TSX:ACB) flagship cannabis store at West Edmonton Mall.

Many of the employees who were temporarily laid-off from the Ontario Stores have been recalled to fulfill customer orders currently being placed online at and by phone, with delivery services expected to be available in the near term. "High Tide is committed to providing all of our customers across Canada with access to legal and safe recreational cannabis during the COVID-19 pandemic," said Raj Grover, President & Chief Executive Officer. "To ensure we are putting the safety of our customers and employees first, the Company has implemented significant measures including click-and-collect ordering, curbside pick-up, hand sanitizer dispensers, increased surface cleaning, hand-washing procedures and door management where required," added Mr. Grover. High Tide continues to monitor the COVID-19 situation closely as it operates its international retail and wholesale businesses, while respecting the orders and guidance issued by public health and other government officials.

Relevium Technologies Inc. (TSXV: RLV) (OTC: RLLVF) announced that it has partnered with Montreal based air purification leaders to launch a new line of residential and office air purification systems.

The systems, which will be added to the Bioganix® CleanCare line of personal health products, contain UV and photocatalytic technology as well as particulate and gas filtration capabilities that are able to eliminate airborne pollutants including viruses and bacteria.

"There is now growing concern that the current and future viral infections could be transmitted via airborne particles and we expect that over the longer-term consumers will become more conscious about in-home prevention" stated Aurelio Useche, CEO of Relevium. Mr. Useche stated further: "We are very proud to partner with Circul-aire® and Asept-Aire®, both leading technologies in air safety with a combined 50 years of experience treating air for very demanding applications including corrosion, odor, pollution and air security"

The product will be available both, in Canada and in the United States through the Company's native website

Global Trac Solutions, Inc. (OTC: PSYC) announced that they have successfully changed their name and corresponding ticker symbol to PSYC in order to align it with their newest business venture objectives.

"PSYC has always been at the forefront of innovative technologies, new industries and market perspective. Most recently, we took an underserved industry in dire need of a cashless payment processing solution and successfully delivered it through MTrac, which quickly evolved into the first significant revenue source in our company's history," said Vanessa Luna, CEO of Global Trac Solutions. "During this process we also assembled a truly unique and powerful network of innovators, partners and leaders from a variety of different new and emerging industries. While the presence we have established for PSYC has afforded us the benefit of being presented with several opportunities for new ventures, our immediate and long term success has remained a top priority and has guided our decision making every step of the way."

"At the core of PSYC's identity is a genuine passion for ingenuity and bold innovations that refuse to be tamed by the status quo. We have positioned ourselves in the past as your resource for discovering Cannabis through our PotSaver publication which will now transition towards acting as a resource center for the psychedelic industry at large. With this in mind, I am both proud and excited to share that over the coming months it is my intent to begin laying the strategic groundwork for PSYC to emerge as a recognized trailblazer in the sector of Psychedelic Medicine, which I believe to be currently on a path to transforming the world of mental health as we know it," Vanessa Luna, continues.

While the subject of medicinal psychedelics remains a hot topic, and there are no assurances as to material matters such as FDA approval, legalization, or general acceptance, in my opinion, it is reminiscent of how medicinal marijuana was hotly debated leading up to its wave of legalization across the U.S. There are a growing number of cities across the country including Denver, Santa Cruz, Portland and Chicago that are pushing for its decriminalization based on the demonstrated benefits of treating mental disorders ranging from depression to anxiety, and PTSD. As this industry begins to lay a foundation for itself, we intend to leverage our team's knowledge of the business aspect of content production, resource availability, and strategic networks, within our anticipated launch of a new multi-level engagement platform. Through subscribership and utilization, as a resource marketplace, PSYC will be centered around the emergence of medicinal psychedelics.

"Some of the recent developments supporting our decision to open up our business expertise in this emerging market surround recent global events taking place, such as the Covid-19 pandemic, and the potentially beneficial effects some of these alternative medicines can have," Vanessa Luna continued.

For example Forbes recently reported: "The Federal administration has green-lit expanded telehealth services, relaxing regulations to reduce exposure to the coronavirus - SARS-CoV-2. This has opened the door to innovation in the medical community, with one company going for a fully remote ketamine treatment option for anxiety and depression."

Renowned places such as John Hopkins Center for Psychedelic & Consciousness Research are at the helm of research and state: "Johns Hopkins is deeply committed to exploring innovative treatments for our patients. Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential." - Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine."

"Over the next several months, we intend to strategically leverage the more than 30 psychedelic-based domains we have secured to launch some of the new and exciting business ventures we believe will be at the forefront of establishing PSYC as a valuable resource within this industry. It is also our intention to continue to focus on MTrac's growth as a trusted resource marketplace within the cannabis industry, and continue to leverage the valuable partnerships we have cultivated over the last three years through its growth to deliver cutting-edge software, marketing and technology solutions to an industry that is still experiencing significant expansion. We also remain focused and dedicated to identifying substantial business ventures that are aligned with the core objectives and fundamentals of our company with an unwavering commitment to effectively position the Company for success and profitability," said Vanessa Luna, CEO.

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accelerate its advancements within the psychedelic medicine arena via the acquisition of a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer. To this extent, the Company announced that it has entered into a definitive agreement to acquire 100% of AltMed Capital Corp.


AltMed's chief executive officer, Dr. Roger McIntyre, is a professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also executive director of the Brain and Cognition Discovery Foundation in Toronto; director, co-chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) in Chicago, Illinois; professor and Nanshan Scholar at Guangzhou Medical University; and adjunct professor at the College of Medicine at Korea University. Furthermore, Dr. McIntyre is a clinical professor at the State University of New York (SUNY) Upstate Medical University, Syracuse, New York, and a clinical professor, Department of Psychiatry and Neurosciences, University of California School of Medicine, Riverside, California.

Clarivate Analytics has named Dr. McIntyre one of "The World's Most Influential Scientific Minds" each year from 2014-2019. Dr. McIntyre is widely regarded as the world's most recognized psychiatrist in relation to mood disorders. He has extensive experience collaborating with private-sector partners, including but not limited to entities within the pharmaceutical industry, the insurance industry and the health care industry in Canada, the United States and globally.

Dr. McIntyre had the vision to implement and develop Canada's first-ever treatment center providing rapid onset treatments for persons with mood disorders, The Canadian Rapid Treatment Centre of Excellence (the "CRTCE"). The CRTCE is involved in knowledge application (using existing scientific research to improve outcomes in depression, PTSD and substance and alcohol use disorders [DPS]); knowledge generation (new research and development); as well as knowledge application (educating health care providers throughout North America and the world on new rapid onset treatments for DPS).

The CRTCE is the only center in North America and globally to demonstrate that rapid onset treatments improve health outcomes in one to two weeks and get people back to work, which is of enormous importance to individuals as well as payers in the private space.

AltMed is a Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer. AltMed has a suite of assets that will accelerate Champignon's multi-pronged business strategy, enabling Champignon to reach the consumer directly via rapid onset medical treatments, with an anticipated rollout of new clinical entities (NCEs) already identified and to be opened across the United States and Canada. Five new clinics in key markets, including New York, Florida and California, are anticipated to be fully operational by Q4 2020.

With this acquisition, Champignon will now have three trials in the Phase I stage and three trials in the preclinical stage during 2020. The Company will also have seven IP patents for its ketamine/psilocybin delivery platforms and formulations.

AltMed maintains a preferred commercial relationship with Canada's largest neuroscience-focused preclinical contract research organization (CRO), InterVivo Solutions. The entities are collaborating to expedite Phase I testing and novel drug development of psychedelic molecules and proprietary delivery systems.

Champignon and AltMed plan to advance psychedelic-derived treatments and establish, via human clinical trials, the most compelling IP portfolio, clinical pipeline and drug development platform in the psychedelic medicine space. In H2 2020, AltMed will commence both comprehensive R&D campaigns as well as clinical trials, to be led and administered by leading M.D.s, clinicians and researchers targeting the following indications:

  • Treatment-Resistant Depression (Dr. Roger McIntyre)
  • Addiction (Dr. Peggi Shepherd DeGroote)
  • PTSD/Traumatic Brian Injury (Dr. David Greenberg and Dr. Michel Rathbone)
  • Aging/Dementia (Dr. DW Molloy)
  • Anxiety/Obsessive-Compulsive Disorder (Dr. Michael Van Amerigan)

"Founded and operated by Dr. McIntyre, the CRTCE has the human capital and unmatched R&D capabilities, with respect to rapid onset treatments such as ketamine, to revolutionize the treatment of depression, PTSD and substance use disorders," stated Gareth Birdsall, CEO of Champignon. "Champignon and AltMed will leverage Dr. McIntyre's expertise, alongside the CRTCE's existing SOPs, data-driven research sets and practitioner education modules, to roll out five unique ketamine clinics across Florida, California and the U.S. Eastern Seaboard. Our additional ketamine clinics are projected to be fully operational by Q4 2020. Furthermore, having previously completed funding rounds, our acquisition of AltMed will further bolster our corporate treasury."

Pat McCutcheon, director of AltMed, stated: "Together with Champignon's existing novel ketamine delivery platforms, associated patents/IP and now advanced clinical infrastructure, we will look to deliver approved, point-of-care psychedelic treatments in clinics throughout Canada and the United States. Ketamine, psilocybin and MDMA have all been fast-tracked by the FDA and Health Canada with respect to R&D in DPS, and we will look to monetize our capabilities and human capital within this domain. Led by our accomplished operational team, comprised of experienced clinicians, academics and thought leaders within dynamic, blue-sky industries, we will be the global leader with regard to the application of rapid onset treatments and will continue to be a first-in-class, vertically integrated center that champions R&D, clinical research, knowledge translation, vocational rehabilitation and psychotherapeutics, offering patient populations a wholesome and comprehensive treatment ecosystem."

Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Learn more about our cannabis podcasts at


To hear more podcasts visit: podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at

Follow us on Cannabis Social Media

Download our Mobile App for iPhone and Android



Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories